Q1 EPS Forecast for Tenax Therapeutics Lowered by Analyst

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Research analysts at Roth Capital cut their Q1 2025 EPS estimates for shares of Tenax Therapeutics in a note issued to investors on Wednesday, March 26th. Roth Capital analyst J. Aschoff now anticipates that the specialty pharmaceutical company will post earnings of ($0.19) per share for the quarter, down from their prior forecast of ($0.18). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.76) EPS, FY2026 earnings at ($0.82) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at $1.99 EPS and FY2029 earnings at $3.27 EPS.

Tenax Therapeutics (NASDAQ:TENX) last issued its quarterly earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.34.

A number of other research firms also recently commented on TENX. StockNews.com initiated coverage on Tenax Therapeutics in a research note on Saturday. They issued a “sell” rating for the company. William Blair restated an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. Finally, Leerink Partners set a $20.00 price target on shares of Tenax Therapeutics in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Tenax Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Price Performance

Shares of NASDAQ TENX opened at $6.49 on Friday. The stock has a market capitalization of $25.73 million, a PE ratio of -1.22 and a beta of 2.20. Tenax Therapeutics has a fifty-two week low of $2.77 and a fifty-two week high of $7.89. The business has a fifty day moving average price of $6.43 and a two-hundred day moving average price of $5.43.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TENX. Janus Henderson Group PLC bought a new position in shares of Tenax Therapeutics in the fourth quarter worth about $1,026,000. Vestal Point Capital LP acquired a new position in Tenax Therapeutics during the 3rd quarter worth approximately $288,000. Sphera Funds Management LTD. bought a new position in Tenax Therapeutics in the 3rd quarter valued at approximately $101,000. Millennium Management LLC acquired a new stake in Tenax Therapeutics in the fourth quarter valued at approximately $166,000. Finally, Two Sigma Investments LP bought a new stake in shares of Tenax Therapeutics during the fourth quarter worth $84,000. Institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.